000868015 001__ 868015
000868015 005__ 20220930130225.0
000868015 0247_ $$2doi$$a10.1016/j.nucmedbio.2019.12.001
000868015 0247_ $$2ISSN$$a0969-8051
000868015 0247_ $$2ISSN$$a1872-9614
000868015 0247_ $$2Handle$$a2128/23987
000868015 0247_ $$2pmid$$apmid:31838339
000868015 0247_ $$2WOS$$aWOS:000528670200001
000868015 037__ $$aFZJ-2019-06608
000868015 082__ $$a570
000868015 1001_ $$0P:(DE-HGF)0$$aSchneider, Daniela$$b0$$eCorresponding author
000868015 245__ $$aInfluence of binding affinity and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of two novel xanthine PET radioligands for the A1 adenosine receptor
000868015 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2020
000868015 3367_ $$2DRIVER$$aarticle
000868015 3367_ $$2DataCite$$aOutput Types/Journal article
000868015 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1579698872_21743
000868015 3367_ $$2BibTeX$$aARTICLE
000868015 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000868015 3367_ $$00$$2EndNote$$aJournal Article
000868015 520__ $$aThe suitability of novel positron emission tomography (PET) radioligands for quantitative in vivo imaging is affected by various physicochemical and pharmacological parameters. In this study, the combined effect of binding affinity, lipophilicity, protein binding and blood plasma level on cerebral pharmacokinetics and PET imaging characteristics of three xanthine-derived A1 adenosine receptor (A1AR) radioligands was investigated in rats.A comparative evaluation of two novel cyclobutyl-substituted xanthine derivatives, 8-cyclobutyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CBX) and 3-(3-[18F]fluoropropyl)-8-(1-methylcyclobutyl)-1-propylxanthine ([18F]MCBX), with the reference A1AR radioligand 8-cyclopentyl-3-(3-[18F]fluoropropyl)-1-propylxanthine ([18F]CPFPX) was conducted. This evaluation included in vitro competition binding assays, in vitro autoradiography and in vivo PET imaging. Differences in cerebral pharmacokinetics and minimal scan duration required for quantification of cerebral distribution volume (VT) were assessed.Measured Ki values of non-labeled CBX, MCBX and CPFPX were 10.0 ± 0.52 nM, 3.3 ± 0.30 nM and 1.4 ± 0.15 nM, respectively (n = 3–4). In vitro autoradiographic binding patterns in rat brain were comparable between the radioligands, as well as the fraction of non-specific binding (1.0–1.9%). In vivo cerebral pharmacokinetics of the novel cyclobutyl-substituted xanthines differed considerably from that of [18F]CPFPX. Brain uptake and VT of [18F]CBX were substantially lower despite the higher concentration of radiotracer in plasma. [18F]MCBX showed comparable uptake and VT, but faster cerebral kinetics than [18F]CPFPX. However, the faster kinetics of [18F]MCBX did not enable the quantification of cerebral VT in a shorter scan time.The combined effect of individual physicochemical and pharmacological properties of a radiotracer on its PET imaging characteristics cannot be readily predicted. In vivo performance of the xanthine A1AR radioligands was mainly influenced by binding affinity; plasma concentrations and cerebral kinetics were of secondary importance.
000868015 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000868015 588__ $$aDataset connected to CrossRef
000868015 7001_ $$0P:(DE-Juel1)131712$$aOskamp, Angela$$b1
000868015 7001_ $$0P:(DE-Juel1)131824$$aHolschbach, Marcus$$b2
000868015 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b3
000868015 7001_ $$0P:(DE-Juel1)131810$$aBier, Dirk$$b4
000868015 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b5
000868015 773__ $$0PERI:(DE-600)1498538-x$$a10.1016/j.nucmedbio.2019.12.001$$gVol. 82-83, p. 1 - 8$$p1 - 8$$tNuclear medicine and biology$$v82-83$$x0969-8051$$y2020
000868015 8564_ $$uhttps://juser.fz-juelich.de/record/868015/files/2020_Schneider_NMB_Influence%20of%20binding%20affinity-3.pdf$$yRestricted
000868015 8564_ $$uhttps://juser.fz-juelich.de/record/868015/files/invoice_19190CV4.pdf
000868015 8564_ $$uhttps://juser.fz-juelich.de/record/868015/files/2020_Schneider_NMB_Influence%20of%20binding%20affinity-3.pdf?subformat=pdfa$$xpdfa$$yRestricted
000868015 8564_ $$uhttps://juser.fz-juelich.de/record/868015/files/Post-Print.pdf$$yPublished on 2019-12-02. Available in OpenAccess from 2020-12-02.
000868015 8564_ $$uhttps://juser.fz-juelich.de/record/868015/files/invoice_19190CV4.pdf?subformat=pdfa$$xpdfa
000868015 8564_ $$uhttps://juser.fz-juelich.de/record/868015/files/Post-Print.pdf?subformat=pdfa$$xpdfa$$yPublished on 2019-12-02. Available in OpenAccess from 2020-12-02.
000868015 8767_ $$819190CV4$$92019-12-06$$d2019-12-16$$eColour charges$$jZahlung erfolgt$$pS0969-8051(19)30513-X
000868015 909CO $$ooai:juser.fz-juelich.de:868015$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000868015 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Forschungszentrum Jülich, INM-2$$b0
000868015 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131712$$aForschungszentrum Jülich$$b1$$kFZJ
000868015 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131824$$aForschungszentrum Jülich$$b2$$kFZJ
000868015 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b3$$kFZJ
000868015 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131810$$aForschungszentrum Jülich$$b4$$kFZJ
000868015 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich$$b5$$kFZJ
000868015 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)131672$$a Heinrich-Heine-Univertsität Düsseldorf$$b5
000868015 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000868015 9141_ $$y2020
000868015 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000868015 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000868015 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000868015 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000868015 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNUCL MED BIOL : 2017
000868015 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000868015 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000868015 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000868015 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000868015 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000868015 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000868015 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000868015 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000868015 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000868015 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000868015 920__ $$lyes
000868015 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000868015 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x1
000868015 980__ $$ajournal
000868015 980__ $$aVDB
000868015 980__ $$aUNRESTRICTED
000868015 980__ $$aI:(DE-Juel1)INM-5-20090406
000868015 980__ $$aI:(DE-Juel1)INM-2-20090406
000868015 980__ $$aAPC
000868015 9801_ $$aAPC
000868015 9801_ $$aFullTexts